Educational information only. Not medical advice. SafePeptideUse sells nothing and is not a substitute for a qualified clinician. Talk to a healthcare professional before making any health decision.
SafePeptideUse logoSafePeptideUse

CJC-1295

Also known as CJC-1295 DAC, CJC-1295 no DAC, Mod GRF 1-29, Modified GRF (1-29)

Not approved in the USGrowth hormone

Last reviewed · Awaiting clinical review

Main safety concerns

It raises growth hormone and IGF-1, so it carries the same cautions as other GH boosters, including avoiding it with active cancer. The DAC and no DAC forms are dosed very differently, so know which one you have.

Educational information, not medical advice. If you have symptoms that worry you, contact a clinician or emergency services.

What is known

A growth hormone releasing hormone analog that raises GH and IGF-1, sold in a long acting (DAC) and a short acting (no DAC) form.

Status:
FDA has flagged safety concerns, including a fast heart rate and flushing. Banned in sport.[5] [6]
Strongest evidence for any claim:

See the evidence claim by claim

On this page

What it is and how it works

CJC-1295 is a synthetic growth hormone releasing hormone (GHRH). It tells the pituitary to release the body's own growth hormone, which raises IGF-1. It comes in two forms. The DAC form (drug affinity complex) binds to albumin and lasts about a week, so a single shot holds GH and IGF-1 up for days. The no DAC form, also called Mod GRF 1-29, is the same core peptide without that anchor. It is thought to act for a much shorter time, but its has never been measured in people, and there are no published human studies of it. Users dose it often to mimic natural GH pulses, and it is the form usually paired with ipamorelin.[1] [3] [4]

Evidence by claim

Each claim is graded on its own. Tap a grade to see what it does and does not mean.

Reported side effects

  • WarningHigher blood sugar[4]Growth hormone can raise blood sugar over time. This is a known class effect, not measured in CJC-1295 studies.
  • CautionInjection site reactions(common)[1] [4]The DAC trial reported only mild side effects and no serious reactions. There is no human data for the no DAC form.
  • CautionFacial flushing or headache(common)[5]From user reports. FDA has also flagged flushing among its safety concerns. There is no human data for the no DAC form.
  • CautionWater retention and puffiness[4]Not reported in the published CJC-1295 trials. Possible in theory because it raises growth hormone, and users report it more with the DAC form.
  • CautionTingling or numbness in the hands(uncommon)[4]A known growth hormone effect, but not reported in CJC-1295 studies.

Interactions and combination risks

  • InfoIpamorelin[4]

    The no DAC form is often paired with ipamorelin in the hope of a bigger GH pulse. No trial has tested this. The DAC form is usually used on its own.

  • CautionDiabetes medicines or insulin[4]

    Because growth hormone raises blood sugar, glucose control may need watching.

Who should avoid it

  • SeriousActive or recent cancer, or a strong family history

    Raising growth hormone and IGF-1 could in theory feed a tumor.

  • SeriousPregnancy or breastfeeding

    No safety data in pregnancy or breastfeeding.

Dosing

Placed after the evidence and risks on purpose. Nothing here is a recommendation for you.

Community reported use, not tested in trials
Route(s)subcutaneous
Typical rangeDAC form: a published trial used 30 or 60 mcg per kg, given weekly or every other week. Users more often take 1 to 2 mg a week. No DAC form (Mod GRF 1-29): community dosing of about 100 mcg per dose, once or twice daily, often before bed and after training, usually with ipamorelin. No published study has tested the no DAC form in people.
FrequencyWeekly for the DAC form. Daily, sometimes more, for the no DAC form.
Cycle guidanceOften run in cycles of several weeks to a few months.
NotesKnow which form you have, because the schedules are opposite. The DAC form is usually used on its own.
[1] [4]

For the equipment itself, see syringes, needles, and the rest of the kit.

Reconstitution

Vial sizes2 mg, 5 mg
DiluentBacteriostatic water for multi dose vials, or sterile water for single use
ConcentrationExample: a 5 mg vial plus 2.5 mL of water gives 2 mg/mL, so 100 mcg of the no DAC form is 0.05 mL, which is 5 units on a U-100 syringe. A 1 mg dose of the DAC form is 0.5 mL, or 50 units.
NotesSold as 2 mg or 5 mg freeze dried vials. The label should say whether it is the DAC or no DAC form.

General reconstitution technique

Units and volume arithmetic

Converts between an amount and syringe units for the vial and diluent you enter. It starts empty and does not suggest an amount. Open the full calculator

Inputs

What do you want to convert?
  1. mg

    Total amount printed on the vial label.

    Sizes sold:
  2. mL

    Volume of bacteriostatic water already in the vial.

  3. Check the unit. 1 mg = 1,000 mcg, so the wrong one is a 1,000x error.

  4. U-100

    Printed on the syringe wrapper. Results over this size are shown as invalid.

Result

Fill in steps 1 to 3 to see the arithmetic. Nothing here is a suggested amount.

Settings live in the address bar, so a pasted link reopens this calculator as you left it.

Educational arithmetic only. It does not choose an amount for you and is not medical or dosing advice. Verify every calculation independently.

Storage and stability

Dry powder (lyophilized)

TemperatureFreeze for long term storage, or 2 to 8 short term
Shelf lifeMany months when frozen
NotesKeep dry and out of light until you mix it.

After mixing

Temperature2 to 8 (refrigerated)
Shelf lifeAbout 2 to 4 weeks
NotesDo not freeze after mixing. Discard if cloudy or discolored.

General storage and stability guide

COA and purity notes

Common adulterantsthe DAC and no DAC forms mislabeled or swapped, underdosed or mislabeled vials
MislabelingThe most common problem is not knowing which form you have, since they are dosed completely differently. The label and COA should clearly say DAC or no DAC.
NotesSold as unregulated research material.

How to read a COA

Sources

  1. [1]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL et al. (Journal of Clinical Endocrinology & Metabolism) 2006 (opens source in a new tab)· Randomized trial

  2. [2]Growth hormone secretagogues: history, mechanism of action, and clinical development

    JCSM Rapid Communications 2020 (opens source in a new tab)· Review

  3. [3]Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

    Ionescu M, Frohman LA (Journal of Clinical Endocrinology & Metabolism) 2006 (opens source in a new tab)· Other

  4. [4]The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

    Dominikowski A et al. (Frontiers in Endocrinology) 2026 (opens source in a new tab)· Review

  5. [5]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    U.S. Food & Drug Administration 2026 (opens source in a new tab)· Regulatory record

  6. [6]World Anti-Doping Code International Standard: Prohibited List 2026

    World Anti-Doping Agency (WADA) 2026 (opens source in a new tab)· Regulatory record

Last reviewed 8 July 2026 · editorial status: reviewed